Our results imply that the development of inhibitors targeting the mitochondrial activity of Stat3 could be of clinical interest as potential anti-tumor agents and could work either by interference with phosphorylation at S727 or by targeting Stat3 for degradation. The gene discussed is STAT3; the disease is neoplasm.